JAKARTA - As many as 472 students of the Army Candidate School (Secapa) Army (AD) recovered from COVID-19. This was conveyed by the Chief of Staff of the Indonesian Army, General TNI Andika Perkasa regarding the latest developments.

"PCR (polymerase chain reaction) laboratory results from the 'swabs' of the 2 patients at Secapa AD until Tuesday, July 21, 2020, in the morning there were four more patients who tested negative. Previously 468 patients were declared cured (bringing the total to 472)," he said. Andika in his written statement, quoted from Antara, Jakarta, Tuesday, July 21.

With the increasing number of recovered COVID-19 patients, said Andika, the handling of COVID-19 patients in the Secapa AD cluster continues to show good news.

"From the beginning, a total of 1,308 positive patients had decreased by 472, and only 836 were left," said Andika.

Of the 836 patients who are still positive for COVID-19, 12 of them are still being treated at the Dustira Army Hospital, Bandung, West Java.

While the rest, namely 824 were in Secapa AD and were isolated, but did not experience any complaints.

In supporting the handling of COVID-19, Kasad has collaborated on research conducted by the Unair Hospital regarding the COVID-19 drug.

On Thursday, July 16, the second PCR laboratory began operating at the Sariningsih Army Hospital, Bandung to speed up the service of examining specimens from swab test results in Bandung and its surroundings, after operating the PCR laboratory at Gatot Soebroto Army Hospital.

The operation is part of the procurement of 68 PCR laboratories for 68 TNI AD hospitals throughout Indonesia. This is to support the Task Force for the Acceleration of Handling COVID-19.

All efforts have been made by the Indonesian Army, both in the procurement of medical equipment for medical personnel and in collaboration with other hospitals to reduce the spread of the corona virus or COVID-19.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)